Optibiotix Health Plc (LON:OPTI) CEO Stephen O’Hara talks to DirectorsTalk about a string of news since Christmas, Stephen gives us an overview of the company’s progress and plans for 2017.
In December 2016 OptiBiotix Health plc announced that it has entered into a joint development agreement with a multinational. The multinational is a major supplier of nutritional solutions to the food, beverage, nutraceutical and pharmaceutical industries within Asia, and increasingly across global markets. In this exclusive interview CEO Stephen O’Hara now names the company as Tata Chemicals Limited (Parent) (NYSE:TATACHEM). At the time all we knew was that the aim of the Agreement was to develop weight management products containing SlimBiome® technology in a range of foods and OTC products which, if successful, would be launched into the Asian market in the second half of 2017. Stephen now sheds further light on this.
Optibiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
